# US 2023/0399687 A1 · Quantitative Multiplex Amplicon Sequencing System

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0399687 A1
- Document ID: US20230399687A1
- Status: Published application
- Kind: A1
- Application number: 18/034,753
- Filed: 2021-11-01
- Published: 2023-12-14
- Earliest claimed: 2020-11-02
- Assignees: NuProbe USA, Inc.; William Marsh Rice University
- Applicants: Nuprobe USA, Inc.; William Marsh Rice University
- Inventors: David Y. ZHANG; Peng DAI; Pengying HAO; Alessandro PINTO
- Web page: https://patentgrep.com/patent/US20230399687A1

## CPC

- C12Q 1/6858: Allele-specific amplification
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention discloses methods of quantitative multiplex amplicon sequencing system for labeling the original DNA sample with an oligonucleotide barcode sequence by polymerase chain reaction, amplifying the genomic region(s) for high-throughput sequencing and quantifying the sequence in DNA sample. The methods allow analyzing a DNA sample comprising between 1 and 10,000 Target Regions for quantifying potential sequence variants and wildtype molecules.

## Claims

### Claim 1

A method for analyzing a DNA sample comprising at least one Target Region for potential sequence variants, the method comprising:
(a) contacting the DNA sample with:
(i) a set of unique molecular identifier (UMI) Primers, wherein each UMI Primer comprises a UMI sequence and a gene-specific sequence that is complementary to a Target Region subsequence;
(ii) a first DNA polymerase; and
(iii) reagents and buffers needed for DNA polymerase extension to generate a mixture;
(b) subjecting the mixture of step (a) to one or more temperatures that allow primer binding and DNA polymerase extension;
(c) removing non-extended UMI Primers to produce a product;
(d) mixing the product of step (c) with:
(i) a second set of DNA primers;
(ii) a second DNA polymerase; and
(iii) reagents and buffers needed for a polymerase chain reaction (PCR),
and performing PCR to produce a PCR product;
(e) subjecting the PCR product produced in step (d) to high-throughput DNA sequencing and obtaining a sequence file comprising next generation sequencing (NGS) reads;
(f) identifying a vetoed UMI sequence, wherein at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or NGS reads containing the vetoed UMI sequence also comprise a wildtype sequence of the at least one Target Region;
(g) removing from consideration all NGS reads comprising the vetoed UMI sequence identified in step (0; and
(h) generating a sequence variant call by quantifying DNA variant molecules based on bioinformatic analysis of the NGS reads that are not removed in step (g).

### Claim 2

A method for analyzing a DNA sample comprising at least one Target Region for potential sequence variants, the method comprising:
(a) contacting the DNA sample with:
(i) a set of unique molecular identifier (UMI) Primers, wherein each UMI Primer comprises a UMI sequence and a gene-specific sequence that is complementary to a Target Region subsequence;
(ii) a first DNA polymerase; and
(iii) reagents and buffers needed for DNA polymerase extension to generate a mixture;
(b) subjecting the mixture of step (a) to temperatures that allow primer binding and DNA polymerase extension;
(c) removing non-extended UMI Primers to produce a product;
(d) mixing the product of (c) with:
(i) a second set of DNA primers;
(ii) a second DNA polymerase; and
(iii) reagents and buffers needed for a polymerase chain reaction (PCR),
and performing PCR to produce a PCR product;
(e) subjecting the PCR product produced in step (d) to high-throughput DNA sequencing and obtaining a sequence file comprising next generation sequencing (NGS) reads;
(f) grouping the NGS reads into at least one UMI Family, wherein each NGS read within a UMI Family comprises an identical UMI sequence and aligns to the same amplicon;
(g) removing from consideration, for each amplicon, all NGS reads in a below-threshold UMI Family; wherein the below-threshold UMI Family comprises a size smaller than X, wherein X is Y % of the mean value for the largest Z UMI Family sizes for the amplicon, wherein Y is between 1% and 20%, and wherein Z is between 1 and 20; and
(h) generating a sequence variant call based on bioinformatic analysis of the NGS reads that were not removed in step (g).

### Claim 3

A method for analyzing a DNA sample comprising at least one Target Region for potential sequence variants, the method comprising:
(a) contacting the DNA sample with:
(i) a set of unique molecular identifier (UMI) Primers, wherein each UMI Primer comprises a UMI sequence and a gene-specific sequence that is complementary to a Target Region subsequence;
(ii) a first DNA polymerase; and
(iii) reagents and buffers needed for DNA polymerase extension to generate a mixture;
(b) subjecting the mixture of step (a) to temperatures that allow primer binding and DNA polymerase extension;
(c) removing non-extended UMI Primers to produce a product;
(d) mixing the product of (c) with:
(i) a second set of DNA primers;
(ii) a second DNA polymerase; and
(iii) reagents and buffers needed for a polymerase chain reaction (PCR),
and performing PCR to produce a PCR product;
(e) subjecting the PCR product produced in step (d) to high-throughput DNA sequencing and obtaining a sequence file comprising next generation sequencing (NGS) reads;
(f) grouping the NGS reads into at least a first UMI Family and a second UMI Family, wherein each NGS read within the first UMI Family comprises a first identical UMI sequence and aligns to a common amplicon, wherein each NGS read within the second UMI Family comprises a second identical UMI sequence and aligns to the common amplicon, and wherein the UMI sequence of the first UMI Family differs by 1 nucleotide or 2 nucleotides as compared to the UMI sequence of the second UMI Family;
(g) removing from consideration the NGS reads in the UMI Family that has the fewest NGS reads between the first UMI Family and the second UMI Family; and
(h) generating a sequence variant call based on bioinformatic analysis of the NGS reads that were not removed in step (g).

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the UMI sequence comprises between 7 degenerate nucleotides and 30 degenerate nucleotides, and wherein each degenerate nucleotide is selected from the group consisting of N, B, D, H, V, S, W, Y, R, M, and K.

### Claim 5 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the high-throughput DNA sequencing comprises sequencing-by-synthesis or nanopore-based sequencing.

### Claim 6 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the sequence file is in a FASTQ format.

### Claim 7 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the first DNA polymerase is a thermostable DNA polymerase.

### Claim 8 (depends on 7)

The method of claim 7, wherein the thermostable DNA polymerase is selected from the group consisting of comprising Taq DNA polymerase, Phusion® DNA polymerase, Q5C) DNA polymerase, and KAPA High Fidelity DNA polymerase.

### Claim 9 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the first DNA polymerase is a non-thermostable DNA polymerase.

### Claim 10 (depends on 9)

The method of claim 9, wherein the non-thermostable DNA polymerase is selected from the group consisting of phi29 DNA polymerase and Bst DNA polymerase.

### Claim 11 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein removing the non-extended UMI Primers in step (c) is performed by a method selected from the group consisting of solid phase reversible immobilization purification, column purification, and enzymatic digestion.

### Claim 12 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein removing the non-extended UMI Primers in step (c) is performed by enzymatic digestion.

### Claim 13 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein a reference sequence of the at least one Target Region comprises multiple DNA sequences for each Target Region comprising single nucleotide polymorphism alleles comprising a population allele frequency of greater than 0.1%.

### Claim 14 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the sequence variant call further comprises removal of the NGS reads when between 1 NGS read and 100 NGS reads comprise an identical UMI sequence.

### Claim 15 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the sequence variant call further comprises removal of the NGS reads when the UMI sequence of the NGS reads does not comprise an appropriate degenerate base design pattern.

### Claim 16 (depends on 1, 2)

The method of claim 1 or 2, wherein the sequence variant call further comprises:
(a) grouping the NGS reads into at least a first UMI Family and a second UMI Family, wherein each NGS read within the first UMI Family comprises a first identical UMI sequence and aligns to a common amplicon, wherein each NGS read within the second UMI Family comprises a second identical UMI sequence and aligns to the same common amplicon, and wherein the UMI sequence of the first UMI Family differs by 1 nucleotide or 2 nucleotides as compared to the UMI sequence of the second UMI Family; and
(b) removing from consideration the NGS reads in the UMI Family that has the fewest NGS reads between the first UMI Family and the second UMI Family.

### Claim 17 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the sequence variant call further comprises identifying a UMI Family Sequence.

### Claim 18 (depends on 2, 3)

The method of claim 2 or 3, wherein the sequence variant call further comprises identifying one or more UMI Families comprising between 1 NGS read to 10 NGS reads comprising a sequence 100% identical to a reference sequence of the at least one Target Region.

### Claim 19 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the sequence variant call further comprises removal of at least one UMI Family comprising a member size smaller than X for each amplicon, wherein X is set as Y % of the mean value for the largest Z UMI Family size(s) in the amplicon, wherein Y is between 1% and 20%, and wherein Z is between 1 and 20.

### Claim 20 (depends on 1, 3)

The method of claim 1 or 3, wherein the sequence variant call further comprises removing from consideration, for each amplicon, all NGS reads in a below-threshold UMI Family; wherein the below-threshold UMI Family comprises a size smaller than X, wherein X is Y % of the mean value for the largest Z UMI Family sizes for the amplicon, wherein Y is between 1% and 20%, and wherein Z is between 1 and 20.

### Claim 21 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the set of UMI primers comprises, in order from 5′ to 3′,
(a) a first universal region;
(b) an optional second region comprising a length of between 1 nucleotide and 50 nucleotides;
(c) a third region comprising a UMI sequence; and
(d) a fourth region comprising a gene-specific sequence that is complementary to a Target Region subsequence.

### Claim 22 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein step (a) further comprises introduction of a set of Outer Primers, and wherein the second set of DNA primers introduced in step (d) comprises a set of Inner Primers, wherein between 3 nucleotides and 20 nucleotides positioned at the 3′ end of the Inner Primer are not subsequences of the set of Outer Primers.

### Claim 23 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein step (d) further comprises variant sequence enrichment.

### Claim 24 (depends on 23)

The method of claim 23, wherein the variant sequence enrichment is performed by blocker displacement amplification (BDA).

### Claim 25 (depends on 24)

The method of claim 24, wherein the BDA comprises amplifying a nucleic acid molecule with:
(a) a BDA forward primer for each target genomic region, wherein the BDA forward primer comprises a region targeting a specific genomic region; and
(b) a BDA blocker for each target genomic region, wherein 4 or more nucleotides at the 3′ end of the BDA forward primer sequence are also present at or near the end of the BDA blocker sequence, and wherein the BDA blocker comprises a 3′ sequence or modification that prevents extension by the DNA polymerase, and wherein the concentration of the BDA blocker is at least twice the concentration of the BDA forward primer.

### Claim 26 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the DNA sample comprises between 1 Target Region and 10,000 Target Regions.

### Claim 27 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the gene specific sequence is at least 90% complementary to the Target Region subsequence.

### Claim 28 (depends on 2)

The method of claim 2, wherein X, Y, and Z are the same integer for all amplicons.

### Claim 29 (depends on 2)

The method of claim 2, wherein X, Y, and Z are not the same integer for all amplicons.

### Claim 30 (depends on 19, 20)

The method of claim 19 or 20, wherein X, Y, and Z are the same integer for all amplicons.

### Claim 31 (depends on 19, 20)

The method of claim 19 or 20, wherein X, Y, and Z are not the same integer for all amplicons.
